Articles From: BioMarin's VIMIZIM(R) (elosulfase alfa) Approved in Australia for Treatment of Morquio A Syndrome to BioSpecifics Technologies Corp. to Host Conference Call to Report Third Quarter 2014 Financial Results on Monday, November 10, 2014


SAN RAFAEL, Calif., Dec.
Sign-up for BioMarin's VIMIZIM(R) (elosulfase alfa) Approved in Australia for Treatment of Morquio A Syndrome investment picks
SAN RAFAEL, Calif., Dec.
Sign-up for BioMarin's VIMIZIM(R) (elosulfase alfa) Approved in Brazil for Treatment of Morquio A Syndrome investment picks
Development of New State-of-the-Art Campus Marks One of the Largest Life Science Lease Transactions Ever in the U.S. as Illumina Continues Its Rapid Growth SAN DIEGO , Jan.
Sign-up for BioMed Realty And Illumina To Create New 360,000 Square Foot World-Class Life Science Campus In Foster City, CA investment picks
Company to Pay Special Dividend of $0.30 per share of Common Stock SAN DIEGO , Dec.
Sign-up for BioMed Realty Sells Rockville, Maryland Asset For $322.5 Million, Resulting In $136.0 Million Net Gain On Sale investment picks
SAN DIEGO , Jan.
Sign-up for BioMed Realty Trust Announces Tax Treatment Of 2014 Distributions investment picks
Increases dividend by 4.0% SAN DIEGO , Dec.
Sign-up for BioMed Realty Trust Declares Fourth Quarter 2014 Common Stock Dividend investment picks
Positive Net Absorption Exceeds 219,000 SF; 2014 FFO Guidance Increased SAN DIEGO , Oct.
Sign-up for BioMed Realty Trust Reports Third Quarter 2014 Financial Results investment picks
SAN DIEGO, Jan.
Sign-up for BioMed Realty Trust to Report 2014 Fourth Quarter and Full-Year Results investment picks
SAN DIEGO, Oct.
Sign-up for BioMed Realty Trust to Report 2014 Third Quarter Results investment picks
bioMérieux, a world leader in the field of in vitro diagnostics, and Illumina (Nasdaq:ILMN), a world leader in genomics, announced they have signed an exclusive agreement to launch a next-generation sequencing (NGS) epidemiology solution for service labs.
Sign-up for bioMérieux and Illumina Enter Agreement to Co-Develop a Next-Generation Sequencing Solution for Epidemiological Monitoring of Bacterial Infections investment picks
2014/11/24
BELLEVILLE, ON , Nov.
Sign-up for Bioniche Life Sciences Inc. Rebrands as Telesta Therapeutics Inc. investment picks
(all figures are in Canadian dollars unless otherwise noted) BELLEVILLE, ON , Nov.
Sign-up for Bioniche Life Sciences Inc. Reports MCNA Update & First Quarter Results investment picks
2014/11/3
http://media.marketwire.com/attachments/201407/263939_BION-ID-Horiz-RGB-300DPI-TM.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1155292&ProfileId=051205&sourceType=1 WEST PALM BEACH, FL --
Sign-up for BioNitrogen Announces Update on Completion of the EPC Report investment picks
2014/11/20
http://media.marketwire.com/attachments/201407/263939_BION-ID-Horiz-RGB-300DPI-TM.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1160676&ProfileId=051205&sourceType=1 WEST PALM BEACH, FL --
Sign-up for BioNitrogen Receives Allocation of $300 Million to Issue Tax-Exempt Bonds for Taylor County Plant investment picks
http://media.marketwire.com/attachments/201007/622573_BionorPharma.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1159268&ProfileId=051205&sourceType=1 OSLO, NORWAY --
Sign-up for Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Safe and Increases CD4 Counts in People Living With HIV investment picks
2014/11/26
"Blue" Friday Savings Available November 28th through December 17th CARLSBAD, Calif.
Sign-up for BioPop Offers Bioluminescent Dino Pet Gift Option for Holiday Gifting investment picks
2014/11/14
BIOQUAL: 2014 BIOQUAL’s Board of Directors has declared a dividend of $0.20 per share for shareholders of record on November 28, 2014, payable on December 15, 2014.
Sign-up for BIOQUAL Presents Financial Results for Fiscal Year 2014 and Declares Dividend investment picks
Double Digit Organic Infusion Revenue Growth; Breakeven Cash Flow from Continuing Operations ELMSFORD, N.Y. , Nov.
Sign-up for BioScrip Reports Third Quarter 2014 Financial Results investment picks
Drop your toys off at any BioScrip company location ELMSFORD, N.Y. , Dec.
Sign-up for BioScrip Supports the Toys for Tots Fund Drive and Collection for Second Year investment picks
ELMSFORD, N.Y. , Nov.
Sign-up for BioScrip to Present at Bank of America Merrill Lynch 2014 Leveraged Finance Conference investment picks
2014/11/10
Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of cardiac arrhythmias, has partnered with advocacy organization StopAfib.org to encourage Americans to Get SMART About Afib SM .
Sign-up for Biosense Webster Teams Up with StopAfib.org to Challenge Americans to Get SMART About AfibSM investment picks
2014/12/19
Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of cardiac arrhythmias, announced the launch of the BIOSENSE WEBSTER ADVANTAGE SM Program, an outcomes-based, risk-sharing program for U.S. hospitals that reinforces the significant patient benefits demonstrated by the company’s THERMOCOOL SMARTTOUCH ® Catheter.
Sign-up for Biosense Webster, Inc. Launches Outcomes-Based, Risk-Sharing Program to Reinforce Significant Patient Benefits Demonstrated by Company’s Leading Contact Force Therapy investment picks
- Auxilium to exercise the exclusive option to expand the field of its license of CCH to include the potential treatment of canine lipoma LYNBROOK, N.Y. , Nov.
Sign-up for BioSpecifics Technologies Corp. Reports Third Quarter 2014 Financial Results investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: BioMarin's VIMIZIM(R) (elosulfase alfa) Approved in Australia for Treatment of Morquio A Syndrome to BioSpecifics Technologies Corp. to Host Conference Call to Report Third Quarter 2014 Financial Results on Monday, November 10, 2014
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent